Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MCLA-117 |
Trade Name | |
Synonyms | Tepoditamab|MCLA117|MCLA 117|anti-CLEC12A-CD3 bispecific antibody |
Drug Descriptions |
Tepoditamab (MCLA-117) is a bispecific antibody that targets CLEC12A and CD3, which potentially results in an increased T-cell response against CLEC12A-expressing tumor cells and tumor cell lysis (PMID: 31286786). |
DrugClasses | CD3 Antibody 99 |
CAS Registry Number | 2044679-53-8 |
NCIT ID | C148141 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
MCLA-117 | MCLA-117 | 0 | 1 |